glp-1 studies GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Mapping the effectiveness and risks
Description
Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.
Why the Stevanato narrative is flawed
The rapid global adoption of GLP-1 based therapies, developed for diabetes and now also used for weight management, has reshaped the pharma landscape
Jules Greene of Good Sense Research explores what this shift means for food and drink brands and where innovation is urgently needed.
On the left, there are options like apples, whole grain crackers, dried fruit, berries, pear, banana, and chopped veggies
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
